Symptomtext
18 month old male patient received expired dose of ACT-HIB vaccine, no AE; Initial information received on 02-Jul-2021 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 18 month old male patient who was vaccinated with an expired dose of suspect HIB (PRP/T) VACCINE [ACT-HIB]. Medical history, medical treatment, vaccination and family history were not provided. Concomitant medications included DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID (DAPTACEL) for Immunisation. On 29-Jun-2021, the patient received a 0.5 ml dose of suspect HIB (PRP/T) VACCINE (lot UJ327AAB and expiry date: 28-Jun-2021) (Frequency: once) via an intramuscular route at an unknown administration site (expired product administered) for prophylactic vaccination. It was an actual medication error case due to expired vaccine used (latency: same day). It was also reported that the caller reported giving an ACT-HIB vaccine to a patient. That was within 24 hours after expiration date. No email was provided by caller. Patient Information Patient age greater 1 year enter as 2 month, 4 month etc. Many pediatric vaccines need month for age. Dosage Information: Frequency -once o Therapy Date: From Date of immunization To - leave blank-given 29Jun2021 by caller Route - route and site- intramuscularly 0.5ml Dose - 0.25 mL to 2 mL for vaccines or 0.1 mL for TB (Tuberculosis) skin test-0.5ml Strength = standard except for Fluzone HD- standard o Indications -Immunization or TB skin test-immunization. Pregnancy- not applicable Last menstrual period, Due date, AE (adverse event) symptoms or no AE. If baby was delivered: delivery date and if baby experienced an adverse event, Inform that they will be receiving a follow up questionnaire, If calling specifically about being added to the pregnancy registry: all pregnancy cases are added to the registry. At the time of reporting, no adverse event was reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.